🫀 En este #DíaMundialdelCorazón impulsamos la concienciación sobre las #EnfermedadesCardiovasculares, centrándonos en algunas de las menos conocidas, entre ellas la #MiocardiopatíaHipertrófica (MCH). 👤 Conoce el testimonio de Lois, a quien le diagnosticaron #MCH a los 16 años y de forma fortuita. "Sufría desde hacía un tiempo los primeros síntomas, pero por desconocimiento no lo había relacionado con una posible patología ni consultado con un médico", explica. Una vez diagnosticado y con un óptimo seguimiento clínico, Lois ha normalizado su MCH. 🗨 Ahora se ofrece a dar un consejo a otras personas que la sufren: "Intentar asimilarla lo antes posible y mirar hacia adelante para convivir con ella más fácilmente. Cuando lo normalizas va todo mejor", comenta Lois. 👉 La Miocardiopatía Hipertrófica Obstructiva es la enfermedad cardiaca hereditaria más común, afectando a 1 de cada 500 pacientes. Dependiendo de la obstrucción puede limitar más o menos la vida diaria de los pacientes. La condición crónica y progresiva de la MCH hace que pueda llegar a tener complicaciones más graves como insuficiencia cardiaca, #arritmias, #ictus y, en alguna ocasión, la #muertesúbita. Por ello es tan importante su diagnóstico precoz. 📰 Conoce su historia en ConSalud.es ➡ https://lnkd.in/d3yDe7Es 📽 Vídeo de la entrevista ▶ https://lnkd.in/d6R_556e #UseHeart #DíaMundialdelCorazón #Cardiomyopathies #CardiomyopathiesMatter #Miocardiopatías #MiocardiopatíaHipertrófica #BMSIberia #BMSEspaña #BMSPortugal #BMSCommunity #BMSTransformingLives #WorkingTogetherforPatients #BMSTransformingPatientsLive
Publicación de Bristol Myers Squibb
Más publicaciones relevantes
-
Our extensive experience in autoimmune diseases and cell therapy drives our commitment to reshaping the treatment landscape for patients. This #LupusAwarenessMonth, Ashley Koegel shares how we’re building upon our legacy in #CARTCellTherapy and #immunology to drive cutting-edge research that has the potential to transform the treatment paradigm for patients with severe and progressive lupus. #DecodedByBMS
Bringing the science of cell therapy into autoimmune diseases
Bristol Myers Squibb en LinkedIn
-
Stroke is a leading cause of death and serious disability worldwide, which is why we’re pursuing transformational research for individuals who are at elevated risk. Our comprehensive Phase 3 Librexia program in collaboration with Johnson & Johnson Innovative Medicine aims to advance research for the prevention of stroke and help address the gap in unmet needs in thrombosis management. #StrokeMonth
-
-
Last year, we participated in a pilot program to recycle lab plastics, including multi-layer flexible bags and PPE, which promises to help us progress in our ongoing sustainability journey. As #EarthMonth closes, learn how we're setting our sights on a more sustainable world for our patients and communities—and our work still ahead: https://bit.ly/3Wjh2gk
-
-
From getting a behind-the-scenes look at our film production studio to experimenting with strawberries to uncover the structure of double helixes, this year’s Take Your Child to Work Day was an inspiring one for our future generation of leaders. Learn more about how we support working parents at every milestone as part of our commitment to fostering a culture of inclusion: https://bit.ly/3UAj3U6
-
-
We have been recognized by the Philadelphia Business Journal for our partnership with Drexel University enabling key STEM education initiatives to build the next generation of scientists who’ll transform patients’ lives through science. Through a grant from BMS, Drexel’s Program has successfully enrolled 91 students in Cell and Gene Therapy, Engineering, Analytics, Manufacturing & Science curriculum, and granted funding to 50 scholars from diverse communities to attend the Biomed Summer Academy with a focus on STEM education and biomedical research. In partnership with BMS, Drexel offered a co-op rotational program to work directly with BMS researchers and scientists. These efforts are just one way we’re invested in the future of STEM education. Learn more about our efforts: https://lnkd.in/eT3wMJM6 #CARTcelltherapy #STEM #partnersinphilanthropy Image credit: Drexel University
-
-
At every step of our environmental sustainability journey, we're searching for ways to minimize our packaging footprint, transition to more reusable and/or recyclable solutions, and advance energy efficiency. This #EarthDay, we're honored to share that we've received the ENERGY STAR Partner of the Year award, which recognizes our commitment to energy management and our ongoing efforts toward a #CleanEnergyFuture. Learn more about our progress to advance the health and well-being of our patients and the planet in our 2023 ESG Report: https://lnkd.in/ePxUhd_6
-
-
We are pleased to announce a worldwide capacity reservation and supply agreement with Cellares for the manufacture of CAR T cell therapies, giving us access to a next-generation fully automated, end-to-end cell therapy manufacturing platform. As part of the agreement, Cellares will optimize and automate select BMS CAR T cell therapies onto its manufacturing platform, the Cell Shuttle. We look forward to our continued work with Cellares and to the promise this agreement will bring for patients benefiting from CAR T therapies. https://bit.ly/446Wfyx
-
-
Acute myeloid #leukemia (AML) is one of the most common types of leukemia in adults, however, common symptoms make it difficult to diagnose. At BMS, with support from our partners, Know AML, Acute Leukemia Advocates Network and others, we work tirelessly towards our goal of broadening the treatment landscape and remain committed to identifying innovative treatments and working toward the potential for improved outcomes for every patient living with this difficult-to-treat blood cancer. As we approach AML Awareness Day, learn more about AML: https://bit.ly/3Uyb4qR
